Study Reveals Blood Sugar Control Halves Heart Disease Risk

Research indicates that individuals with prediabetes who successfully manage their blood sugar levels can significantly reduce their risk of death from heart disease or heart failure by up to 50%. This finding comes from a study published on December 12, 2023, in the journal Lancet Diabetes & Endocrinology, and highlights the importance of addressing prediabetes early.

Prediabetes is a condition affecting approximately 38 per cent of adults in the United States, characterized by elevated blood sugar levels that do not yet meet the criteria for diabetes. The study pointed out that individuals who achieved “remission,” where their glucose levels returned to normal, experienced a markedly lower risk of cardiovascular complications two decades later compared to those who did not normalize their levels.

Dr. Latha Palaniappan, associate dean for research at Stanford Medicine, remarked, “That is an incredible finding and really gives people hope that what they do today will have an effect two decades from now.” While there has long been evidence linking Type 2 diabetes to increased risks of heart attacks and heart failure, the specific relationship between prediabetes and cardiovascular disease has been less clear.

The urgency of these findings may prompt both patients and healthcare providers to take prediabetes more seriously. Current guidelines primarily stress weight loss and lifestyle changes to prevent progression to Type 2 diabetes but do not specifically recommend lowering blood glucose levels to a range below those indicative of prediabetes.

Longitudinal Insights from Groundbreaking Trials

The recent research builds upon data from two significant trials, including the US Diabetes Prevention Program, conducted from 1996 to 2001. This trial evaluated three interventions aimed at reducing the onset of Type 2 diabetes among prediabetic participants: an intensive lifestyle program focused on diet and exercise, the oral medication metformin, and a placebo group. Findings revealed that the lifestyle program led to a 58 per cent reduction in the development of Type 2 diabetes over three years, while metformin reduced the risk by 31 per cent.

Two decades later, the study found that about 11 per cent of participants had achieved normal glucose levels within one year, regardless of the intervention they received. This subgroup had a 50% lower risk of cardiovascular-related death or hospitalization compared to those who did not normalize their glucose levels, even after adjusting for various factors, including the development of full-blown diabetes.

To further validate these findings, the research team also analyzed data from a similar diabetes prevention trial conducted in China. Approximately 13 per cent of participants with elevated glucose achieved normal levels after six years. Remarkably, thirty years later, this group demonstrated a 51 per cent lower risk of death from heart disease and hospitalizations than those who did not reach normal glucose levels.

Dr. Elizabeth Selvin, a professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health, noted, “It’s interesting that this short-term intervention period has these very long-term effects.”

The Broader Implications for Health Management

Normalizing glucose levels, whether through lifestyle changes or other means, can lead to reduced abdominal fat, decreased inflammation, and improved insulin sensitivity. Dr. Andreas Birkenfeld, the chair of the department of diabetology at University Hospital Tubingen in Germany, emphasized that the study’s results highlight the significant health benefits of maintaining normal glucose levels.

Despite the positive findings, the researchers acknowledged the challenges in determining which participants maintained lifestyle changes post-intervention. Dr. Jonathan Newman, clinical research director at the Center for the Prevention of Cardiovascular Disease at NYU Langone Heart, pointed out that unmeasured differences might contribute to the varied outcomes observed between those who achieved remission and those who did not.

Moreover, achieving normal glucose levels in both the U.S. and China trials remained a significant challenge, as very few participants managed to do so. Judy Regensteiner, director of the Ludeman Family Center for Women’s Health Research at the University of Colorado Anschutz Medical Campus, who was involved in the Diabetes Prevention Program trial but not the current study, remarked, “It’s a good proof of concept. But, if these really well-done studies have low success rates in getting people to those numbers, what do we do differently?”

Experts pointed out that the new class of GLP-1 medications, which help control blood sugar and aid in weight loss, was not included in the initial trials from the 1980s and 1990s. Dr. Selvin emphasized that while lifestyle interventions remain the primary strategy, combining them with newer medications presents an exciting opportunity for better management of prediabetes and its associated risks.

While lowering blood glucose levels is essential, it is only one part of a comprehensive approach to reducing cardiovascular disease risk. Maintaining a healthy weight, adhering to a balanced diet, and engaging in regular exercise are all critical components. Dr. Newman highlighted that prediabetes often signifies broader metabolic dysfunction, making it crucial to address multiple health factors rather than focusing solely on blood sugar levels.

The findings from this research underscore the importance of proactive health management for individuals with prediabetes. By emphasizing the potential long-term benefits of blood sugar control, healthcare professionals can encourage patients to implement lifestyle changes that may lead to better health outcomes in the future.